"Strong growth", "rapid growth", "continual growth", growth, growth, growth is all throughout the preso! Looking forward to watching it all unfold. The $1.4m financial processing revenue was "run rate" (annualised) figure based on reported revenue of 350k in Dec quarter, ie. 350k x 4 = $1.4M. But we wouldn't be far off given we should expect at least 700k financial processing revenue in 2H FY18 (350k x 2 quarters) in addition to the 500k reported in 1H FY18, ie. at least $1.2M. Which means total revenue of $6.2M and at least 75% growth on FY17! Crazy thing is I can't see it slowing down - we're cashed up, debt free, cutting costs, have great management and Chinese tech investors onboard, just skimmed the surface of emerging markets and revenue "growth" happening everywhere. Great stock to hold at the moment, especially given we're going to run at profits in 2H FY18. Plus 82% top 20 shareholders!
- Forums
- ASX - By Stock
- NOV
- Ann: Novatti Corporate Overview - March 2018
Ann: Novatti Corporate Overview - March 2018, page-4
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NOV (ASX) to my watchlist
(20min delay)
|
|||||
Last
4.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $14.94M |
Open | High | Low | Value | Volume |
4.0¢ | 4.2¢ | 3.9¢ | $11.72K | 297.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 220794 | 3.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
4.2¢ | 151006 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 220794 | 0.039 |
3 | 103947 | 0.038 |
2 | 145000 | 0.037 |
1 | 277777 | 0.036 |
2 | 228000 | 0.035 |
Price($) | Vol. | No. |
---|---|---|
0.042 | 151006 | 2 |
0.043 | 66961 | 1 |
0.044 | 4233 | 1 |
0.045 | 25000 | 1 |
0.047 | 51877 | 4 |
Last trade - 16.10pm 12/06/2024 (20 minute delay) ? |
|
|||||
Last
4.1¢ |
  |
Change
0.000 ( 2.50 %) |
|||
Open | High | Low | Volume | ||
3.9¢ | 4.1¢ | 3.9¢ | 44928 | ||
Last updated 15.55pm 12/06/2024 ? |
Featured News
NOV (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, CEO
James Graham
CEO
SPONSORED BY The Market Online